Regulators

The rise in insulin prices has become a heated topic in healthcare discussions, drawing scrutiny towards the roles played by pharmacy benefit managers (PBMs) and pharmaceutical companies. Recently, Texas Attorney General Ken Paxton has taken a significant legal step by suing major PBMs and pharma

New regulations often elicit a mix of anticipation and apprehension, and the EU AI Act is no exception, especially in the life sciences and digital health sectors. As companies navigate the evolving regulatory landscape, understanding the implications of this legislative framework becomes essential

The cost of insulin has surged dramatically over the past decades, burdening patients who rely on this life-saving medication. Rising costs have drawn scrutiny from regulators, lawmakers, and consumers, leading to investigations into the pharmaceutical industry's pricing mechanisms. Among the

The call for legislative intervention to overturn the FDA's final rule on the regulation of laboratory-developed tests (LDTs) has intensified. The Association for Diagnostics and Laboratory Medicine (ADLM) has been at the forefront, urging lawmakers to take action against the FDA's new

The Biden administration has taken a remarkable step forward in mental health care by finalizing rules that expand mental health coverage standards in private insurance plans. This bold move aims to address the longstanding disparities between mental and physical health benefits, ensuring millions

The opioid crisis has left an indelible mark on American society, thrusting numerous stakeholders, particularly drug distributors, into the spotlight. The recent $300 million settlement by McKesson, Cardinal, and Cencora represents one of the latest significant efforts to address the multifaceted